All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 31, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for May 24, 2023

May 24, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Biolase, Microbot Medical.
Read More
Map of Australia with pills, vials and syringe

Ausmedtech 2023: Should Australian med techs bother commercializing products at home?

May 24, 2023
By Tamra Sami
No Comments
With venture capital quite scarce, Australian med techs often question whether it makes sense to try to commercialize their products in their home market or whether they should partner to go offshore, but there are other options, said presenters at the Ausmedtech 2023 conference in Adelaide May 24.
Read More
Picture-1--A-Maestro-moon-surgical-(002).jpg

Moon Surgical secures $55.4M for its laparoscopic robot commercialization preparation

May 24, 2023
By Bernard Banga
No Comments
Moon Surgical SAS secured a new $55.4 million round of financing to strengthen the development and commercialization of its Maestro robotic system for laparoscopic surgery.
Read More
DNA, dollars illustration

Elevatebio closes $401M series D as Life Edit subsidiary nabs Novo Nordisk deal

May 24, 2023
By Jennifer Boggs
No Comments
In its bid to become, as Chairman and CEO David Hallal said, the “world’s most indispensable cell and gene therapy technology company,” Elevatebio LLC disclosed a $401 million series D round with support from new and existing investors. At the same time, the company’s Life Edit Therapeutics Inc. affiliate inked a potential billion-dollar collaboration focused on gene editing therapies.
Read More

Financings for May 24, 2023

May 24, 2023
No Comments
Biopharmas raising money in public or private financings, including: Ambrx, Biodexa, Dermata, Inprother, Kamada, Ocugen, Phathom, Resolutionrx.
Read More

Financings for May 23, 2023

May 23, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Alcon, Lifecore Biomedical.
Read More

Financings for May 23, 2023

May 23, 2023
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Drug Farm.
Read More

Icosavax raises $67.8M and posts strong phase I RSV data

May 23, 2023
By Lee Landenberger
No Comments
While pricing a $67.8 million registered direct offering, Icosavax Inc. also released positive top-line interim data from a phase I study of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus in older adults.
Read More
RNA illustration
Newco news

Top VC round in 2023: Renagade breaks the RNA mold with its series A

May 23, 2023
By Karen Carey
No Comments
Launching with a $300 million series A financing, Renagade Therapeutics Inc. has set out to target disease on a large scale – at every point throughout the human body where disease forms – through its RNA platform designed to deliver, code, edit and insert genetic information. The round, led by founding investors MPM Bioimpact and F2 Ventures, is the largest venture capital (VC) round for a U.S.-based biopharma company this year, and it is among the top series A rounds for the industry to date.
Read More
Huang Baohua, founder and CEO, Coherent Biopharma

Coherent Biopharma nets $100M in financing for Bi-XDC drugs

May 23, 2023
By Doris Yu
No Comments
Coherent Biopharma Co. Ltd. raised $100 million in series B and B+ financing rounds to step up its efforts to develop its bi-targeting ligand-drug conjugate (Bi-XDC) drugs and get them to market. Suzhou, China-based Coherent plans to use its newly expanded war chest to support the clinical trials of three candidates, CBP-1008, CBP-1018 and CBP-1019, as well as an IND application for CBP-8008 in China and the U.S., the company told BioWorld.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 391 392 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2023.
  • FDA approved icons and medical professional

    Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

    BioWorld
    Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...
  • Illustration of pancreas

    Gene therapy to reverse T2D shows proof of concept at ASGCT

    BioWorld
    The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...
  • Clinical data illustration

    Medtronic, Philips, Edwards late-breaking study data spotlighted at EuroPCR

    BioWorld MedTech
    Among the many companies presenting data at the EuroPCR conference in Paris, several late breaking trials from heavy hitters Medtronic plc, Royal Phillips NV and...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing